Abstract
Abstract Functional Study of DCC Gene in Multiple Myeloma Cell Lines ABSTRACT INTRODUCTION: Multiple Myeloma (MM) is an incurable hematological malignancy characterized by multiorgan dysfunction as a result of bone marrow infiltration by malignant cells and the systemic damage of monoclonal circulating protein. Despite considerable progress in understanding MM biology, the molecular basis of this disease still remains open to debate. Previous data showed that DCC gene hypermethylation is significantly correlated with poor prognosis of MM patients. However, the involvement of DCC in the tumorigenesis process of MM remains unclear. PURPOSE: To better understand the role of DCC in this pathology through gene silencing in MM cell lines and evaluation of its interference in different tumorigenic processes. METHODS: The DCC gene expression was evaluated in three MM cell lines (RPMI-8226 and U266) and promoter methylation profile of this gene in the three cell lines was determined. The presence of DCC protein was confirmed by Western blotting (WB). The DCC expression was silenced by esiRNA and transfections were performed by electroporation. RESULTS: We detected the presence of aberrant methylation in DCC promoter in RPMI-8226, a cell line with undetectable expression of DCC. On the other hand, DCC was not methylated in U266, which present expression of DCC at mRNA and protein level. For this reason, DCC was silenced in U266 with esiRNA and its impact in the apoptosis, cell viability, proliferation and cell cycle processes was evaluated in this cell line. Support by FAPESP Citation Format: Dorival Mendes Rodrigues-Junior, Thais Priscilla Biassi, Viviane Carlin, Joel Machado-Junior, André Luiz Vettore. Functional Study of DCC Gene in multiple myeloma mell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2457. doi:10.1158/1538-7445.AM2014-2457
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
